e-learning
resources
Amsterdam 2015
Sunday, 27.09.2015
New data on established treatments for COPD
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Population pharmacokinetics of A1-PI in patients with Alpha-1 antitrypsin deficiency
Michael Tortorici (King of Prussia, United States of America), Michael A. Tortorici, Oliver Vit, Martin Bexon, Robert Sandhaus, Jonathan Burdon, Eeva Piitulainen, Niels Seersholm, James Stocks, N. Gerard McElvaney, Kenneth R. Chapman, Jonathan Edelman
Source:
International Congress 2015 – New data on established treatments for COPD
Session:
New data on established treatments for COPD
Session type:
Poster Discussion
Number:
1486
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Michael Tortorici (King of Prussia, United States of America), Michael A. Tortorici, Oliver Vit, Martin Bexon, Robert Sandhaus, Jonathan Burdon, Eeva Piitulainen, Niels Seersholm, James Stocks, N. Gerard McElvaney, Kenneth R. Chapman, Jonathan Edelman. Population pharmacokinetics of A1-PI in patients with Alpha-1 antitrypsin deficiency. Eur Respir J 2015; 46: Suppl. 59, 1486
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Observational cohort study of pulmonary exacerbations in alpha-1 antitrypsin deficiency
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Related content which might interest you:
Assessment of A1-PI dose-exposure and exposure-response relationships in patients with Alpha-1 antitrypsin inhibitor deficiency
Source: International Congress 2015 – New data on established treatments for COPD
Year: 2015
Pulmonary rehabilitation (PR) in patients with COPD due to alpha-1 antitrypsin deficiency (AATD): 15 years experience at the Maugeri Institute
Source: Annual Congress 2013 –The best posters in pulmonary rehabilitation
Year: 2013
Bronchiectasis but not emphysema is more prevalent in non-PiZ alpha-1 antitrypsin deficiency (AATD) COPD than in usual COPD
Source: International Congress 2014 – Genetics and environmental factors underlying asthma and COPD
Year: 2014
Degree of knowledge among physicians about the diagnosis and treatment of alpha-1 antitrypsin deficiency
Source: International Congress 2015 – COPD: chronic disease and comorbidities
Year: 2015
Diagnosis of alpha 1 antitrypsin deficiency in primary care
Source: International Congress 2015 – Management of COPD and other respiratory diseases in primary care
Year: 2015
The Irish national alpha-1 antitrypsin deficiency targeted detection programme
Source: Annual Congress 2013 –Epidemiology of respiratory disease
Year: 2013
Long-term evolution of individuals with alpha1 antitrypsin deficiency from the Spanish registry
Source: International Congress 2015 – New frontiers in the management of interstitial and orphan lung diseases
Year: 2015
Screening of alpha-1 antitrypsin deficiency in a blood donors cohort of the North-Italian area
Source: International Congress 2015 – Prevalence of respiratory disease
Year: 2015
Alpha-1 antitrypsin deficiency in patients with bronchiectasis: data from the European Bronchiectasis Registry EMBARC
Source: Virtual Congress 2020 – New investigations of bronchiectasis and non-tuberculous mycobacteria
Year: 2020
The national alpha-1 antitrypsin deficiency registry in Poland
Source: International Congress 2015 – Chronic airway disorders: miscellaneous aspects
Year: 2015
Differences of disease phenotypes in individuals with alpha-1-antitrypsin deficiency with genotypes PiZZ and PiSZ - Analysis from the German registry
Source: International Congress 2016 – Phenotyping and monitoring airway diseases
Year: 2016
Prevalence of alpha-1 antitrypsin deficiency (AATD) and frequencies of alleles PI*S and PI*Z in patients with COPD in Brazil
Source: Annual Congress 2013 –Assessing the prevalence of COPD in the general population
Year: 2013
Screening for alpha-1 antitrypsin deficiency in Polish lung or liver disease patients
Source: Annual Congress 2011 - Lung development and neoplasia
Year: 2011
Characteristics of zz alpha-1 antitrypsin deficiency patients on the Irish national registry
Source: Annual Congress 2012 - Inflammation in airway diseases: diagnosis and management
Year: 2012
COPD and alpha-1 antitrypsin deficiency emphysema: characteristics and survival after Lung Transplantation
Source: International Congress 2018 – Moving lung transplantation forward
Year: 2018
Alpha-1 antitrypsin deficiency in patients with COPD/emphysema, bronchiectasis and asthma
Source: Virtual Congress 2020 – New biomarkers for management of obstructive diseases
Year: 2020
Clinical features of alpha one antitrypsin deficiency in COPD
Source: Annual Congress 2012 - Inflammation in airway diseases: diagnosis and management
Year: 2012
Lung transplantation in alpha 1 antitrypsin deficiency
Source: International Congress 2015 – Outcomes of lung transplantation
Year: 2015
Identification of a novel SERPINA-1 mutation causing alpha-1 antitrypsin deficiency in a patient with severe dyspnea
Source: International Congress 2016 – Molecular targets in pulmonary disease
Year: 2016
Alpha-1 antitrypsin deficiency in COPD patients: Time to count it in!
Source: Virtual Congress 2020 – Pharmacological management of COPD
Year: 2020
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept